<DOC>
	<DOC>NCT02525107</DOC>
	<brief_summary>140 SCD patients [70 on Hydroxyurea] will receive Omega-3 capsules whereas another 140 SCD patients [70 on Hydroxyurea] will receive placebo and will be recruited from the Sultan Qaboos University Hospital [SQUH] haematology specialty clinics. Patients will be randomized in a 1:1 ratio to receive placebo or Omega-3 for 52 weeks. The aim is to investigate the therapeutic potential of omega-3 fatty acids in the prevention of vaso-occlusive crisis in Omani patients with sickle cell disease[SCD].</brief_summary>
	<brief_title>Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Moderate to severe Sickle cell disease patients. Patients already receiving Hydroxyurea[HU] are eligible for the study. Patients able and willing to comply with the procedures in the study protocol. Acute episodes (infection, vasoocclusive crises (VOC), acute chest syndrome (ACS), stroke, priapism, splenic sequestration) in the past one month before enrolment. Previous stroke, and other comorbid diseases like Essential Hypertension, Cardiomyopathy and Heart failure, Diabetes, Chronic Renal Failure. Patients with a history of adverse reaction to omega3 fatty acid supplementation. Blood transfusion in the previous 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Prevention of Vaso Occlusive Painful Crisis</keyword>
</DOC>